(Q34707883)

4 August 2017

1 reference

title

A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy (English)

1 reference

4 August 2017

1 reference

Fitzpatrick BJ

1

1 reference

4 August 2017

Standiford HC

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 1982

1 reference

4 August 2017

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

197-212

1 reference

Role of the 7 alpha-methoxy and side-chain carboxyl of moxalactam in beta-lactamase stability and antibacterial activity

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In Vitro Activity of LY127935

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative Activities of the Oxa-β-Lactam LY127935, Cefotaxime, Cefoperazone, Cefamandole, and Ticarcillin Against Multiply Resistant Gram-Negative Bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro activity of LY127935.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro activities of cefotaxime and moxalactam (LY127935) against Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative in-vivo activity of Sch 29482 and six other extended spectrum cephalosporins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

The in-vitro activity of ceftazidime against clinically important pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Correlation of moxalactam (LY127935) susceptibility tests by disk diffusion and agar plate dilution methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative In Vitro Activity of New Beta-Lactam Antibiotics Against Anaerobic Bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Serum Bactericidal Activity of Moxalactam and Cefotaxime With and Without Tobramycin Against Pseudomonas aeruginosa and Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics of moxalactam in subjects with normal and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam, and Ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Clinical pharmacology of moxalactam in patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Treatment of experimental Haemophilus influenzae type b meningitis with 1-oxa-beta-lactam (LY127935).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam pharmacokinetics during hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Pharmacokinetics of moxalactam in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Therapy of obstetrical infections with moxalactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Intravenous cefotaxime in children with bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Therapy of lower respiratory tract infections with moxalactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Moxalactam therapy for a wide spectrum of bacterial infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Clinical evaluation of moxalactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03187.X

10.1002/J.1875-9114.1982.TB03187.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference